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GENERAL COMMENTS
This is an interesting study, one that I view as hypothesis generating. It uses a robust methodology to address a question posed by patients about their gout. I don't have a huge number of comments.
1. Is a 12 month baseline period with no codes for hearing loss long enough to make this a 'clean' baseline cohort? One would imagine that hearing loss is diagnosed and then probably forgotten about once it is treated with hearing aids, or if it is not impacting too much on function. I am not US based so I don't know if non-active conditions are coded during consultations. It would be good to clarify this.
2. There is much speculation in the discussion about potential mechanisms, however discussing next steps would be of huge value. How are the authors going to go from this work to another study to help clarify the question further?
3. I think it would be hugely value to extend this work with assessment of SUA. As if the hypothesis is of oxidative stress, and a subgroup were identified that had adequete treatment with suppressed SUA then further information could be attained about this hypothesis. Similar to the BMJ angina-allopurinol study.
VERSION 1 -AUTHOR RESPONSE
Reviewers' Comments to Author:
Reviewer: 1 Reviewer Name: Nicola Dalbeth Institution and Country: University of Auckland, New Zealand Competing Interests: I have collaborated with Dr Singh on a number of gout related projects
This analysis of Medicare claims data shows an association between gout and incident hearing loss in older people. This association has not been reported previously, so is a novel finding. There are some limitations to the study that impact on the clinical relevance of the study: 1. The association is quite weak with a HR of 1.32-1.44. It is difficult to know how clinically relevant this finding is.
Response: We have added discussion related to the clinical relevance, as suggested.
"Our finding of the 32-44% increased hazards of hearing loss associated with the diagnosis of gout must be interpreted in proper clinical context. An early recognition of hearing loss related to the presence of gout may have a meaningful clinical implication. Although the increased risk is not 2-or 3-fold higher (not an uncommon finding in epidemiological studies for a single factor vs. polygenic disease), it seems clinically meaningful. Screening and diagnosis of hearing loss is relatively inexpensive, and the economic impact of hearing loss is large, estimated at $US750 billion lost each year globally 27 . Hearing loss has a significant impact on quality of life, both physical and mental/emotional health, and a higher severity of hearing loss is associated with larger deficits in quality of life 4 ; it is also associated with cognitive decline 28 . Hearing-aids not only improve the hearing, but may also protect against cognitive impairment and disability, improving quality of life of aged people 6 . With an increasing emphasis on prevention of hearing loss 29 , recognition of novel risk factors, such as gout, pave the way for an early diagnosis and potentially preventing more severe hearing loss in an aging population, and decreasing the overall associated costs and disability." 2.
I am concerned that there is insufficient adjustment for potentially confounding variables such as prior manual occupations (noting that noise induced hearing loss is likely to be a major contributor to hearing old in older people), exposure to ototoxic drugs, etc.
Response: We agree and have added this as a study limitation, as suggested "Due to an observational study design, residual confounding from unmeasured variables (prior noise exposure, or the use of ototoxic drugs) is possible, despite the fact that we controlled for several potential confounders."
3.
This appears to be one of a large series of papers published by these authors using the same database. There does not appear to be any adjustment for repeated testing within the analysis.
Response: We have added this limitation, as suggested "We examined additional outcomes in other related papers but did not make any adjustment for multiple testing in this analysis; however even after correction for 15 hypothesis-testing, the Bonferroni corrected p-value was 0.003, which was higher than the p-value reported in our study. This means that even when corrected for multiple testing, the current study findings would still be significant."
4.
The authors spend a lot of the paper postulating that this result may be related to oxidative stress or inflammation; yet provide no clear evidence for this. To interrogate this hypothesis more I would be interested in seeing a more detailed analysis examining associations with gout for a number of different conditions associated with oxidative stress or inflammation. More details about the CRP or serum urate would have greatly improved the analysis.
Response: We agree, but these laboratory variables are not available in Medicare data, as discussed in study limitations section, which has been clarified further. Due to the scope of the project, we were unable to examine other conditions with vs. without oxidative stress.
"We did not have access to laboratory measures including serum urate, or markers of inflammation (e.g., C-reactive protein) or oxidative stress."
Reviewer: 2 Reviewer Name: B Spaetgens Institution and Country: Maastricht UMC, the Netherlands Competing Interests: none declared Singh and Cleveland performed a retrospective cohort study using a 5% random sample of >65yr WE Adults using MediCare Claims Data.This is the first study to address the issue whether gout is associated with hearing loss in older adults. Apparently it is (HR 1.44).
Overall the study is methodologically sound and well written. The introduction has an adequately generated hypothesis. The study design, data analysis and discussion (adequately mentioning limitations) are clear and appropriatie. This is an interesting study, one that I view as hypothesis generating. It uses a robust methodology to address a question posed by patients about their gout. I don't have a huge number of comments.
1. Is a 12 month baseline period with no codes for hearing loss long enough to make this a 'clean' baseline cohort? One would imagine that hearing loss is diagnosed and then probably forgotten about once it is treated with hearing aids, or if it is not impacting too much on function. I am not WE based so I don't know if non-active conditions are coded during consultations. It would be good to clarify this.
Response: Similar to treated hypertension, once diagnosed, hearing loss is a part of patient's current diagnoses, regardless of the treatment with hearing aids. In the U.S., a primary care physician, or a specialist, would code hearing loss during a patient's follow-up visit, since the patient still has the disease. More detailed explanation for 12-month baseline period is now provided.
"It is possible that a longer baseline period with no diagnosis would further increase the possibility of not missing the baseline diagnosis of hearing loss; however, this would lead to smaller cohort for observation of incident hearing loss cases and a shorter observation period. Weighing pros and cons, we chose to keep baseline period at 12-month, which is standard for Medicare database studies (12-18 months)" 2. There is much speculation in the discussion about potential mechanisms, however discussing next steps would be of huge value. How are the authors going to go from this work to another study to help clarify the question further?
Response: We have added this to the discussion, as suggested "We hypothesize that hyperuricemia-related inflammation and oxidative stress pathways potentially link gout to hearing loss. These hypotheses need to be tested in future studies, which should examine as to which factors contribute to this increased risk and to what extent." 3. I think it would be hugely value to extend this work with assessment of SUA. As if the hypothesis is of oxidative stress, and a subgroup were identified that had adequete treatment with suppressed SUA then further information could be attained about this hypothesis. Similar to the BMJ angina-allopurinol study.
Response: We agree and have added this to the discussion, as suggested "Randomized trials of urate-lowering drugs and/or those that reduce oxidative stress independent of urate-lowering are needed to assess their effect on reduction of the risk of hearing loss in older adults." FORMATTING AMENDMENTS (if any) Required amendments will be listed here; please include these changes in your revised version: Authors must include a statement in the Methods section of the manuscript under the sub-heading 'Patient and Public Involvement'. This should provide a brief response to the following questions:
-How was the development of the research question and outcome measures informed by patients' priorities, experience, and preferences? -How did you involve patients in the design of this study? -Were patients involved in the recruitment to and conduct of the study? -How will the results be disseminated to study participants? -For randomised controlled trials, was the burden of the intervention assessed by patients themselves?
-Patient advisers should also be thanked in the contributorship statement/acknowledgements. If patients and or public were not involved please state this.
Response: We have added this paragraph as suggested. Acknowledgement includes reference to our patients. "The development of the research question was informed by several patients with gout seen at the UAB general rheumatology clinic and the UAB gout clinic who asked us about the possible link of gout and their chronic condition/s, including hearing loss. This prompted us to perform this study. Patients were not involved in study design or conduct. Administrative dataset does not contain identifiable information for patients, and therefore patients can not be contacted for dissemination of study findings. Publication of the manuscript is our planned dissemination of the findings to the public." 
GENERAL COMMENTS
The authors have addressed my comments adequately
